Biogen Exploring Tecfidera Safety Perceptions As Sales Slowdown Continues
This article was originally published in The Pink Sheet Daily
Executive Summary
Slowing sales growth continues for Biogen’s Tecfidera in the first quarter, due in part to lingering questions regarding safety. In an April 24 earnings call, the company also provided an update on Phase III study plans for its Alzheimer’s candidate, aducanumab.
You may also be interested in...
Spotlight Returns To Biogen R&D To Sustain Success
After an impressive commercial run for Biogen Idec, with four drug launches in two years, it’s up to R&D to deliver more innovative medicines. The bar is high in the areas of neurology Biogen is exploring; Chief Medical Officer Alfred Sandrock discussed the company’s R&D momentum in a recent interview.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.